Test for LDL subtype helps manage coronary risk
Answers from the Lab
Small dense LDL cholesterol (sdLDL-c) is an important biomarker for understanding a patient's risk of coronary heart disease. In this test-specific episode of the "Answers From the Lab" podcast, Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' assay measuring sdLDL-c concentrations aids clinical management of patients with high LDL or "bad" cholesterol.
"sdLDL-c is a particular type of harmful cholesterol that is thought to be highly atherogenic," Dr. Vasile says. "Patients with elevated LDL cholesterol might or might not have high small dense LDL. The sdLDL-c assay identifies the category of patients at higher risk, who might otherwise be missed in clinical practice."
The results can directly impact clinical care.
"The higher the cholesterol concentration in these small dense particles, the higher the risk of future cardiovascular events," Dr. Donato says. "sdLDL-c test results can help guide decisions about initiating or intensifying a pharmacotherapy, to lower overall atherosclerotic cardiovascular disease risk."
Listen to learn more about Mayo Clinic Laboratories' sdLDL-c assay.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Aiding in risk management of lipoprotein disorders associated with cardiovascular disease when used in conjunction with other lipid measurements and clinical evaluation.
Patient Preparation: Fasting: Overnight (8-12 hours)
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.